Evidence map›Paper›PMID 41467351›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2026

Nonhematopoietic MicroRNA-26b

Linsey J F Peters, Kiril Bidzhekov, Remco T A Megens, Yvonne Jansen, Han Jin, Alexander Jans, Cheng Lin, Markus Haberbosch, Matthias Bartneck, Erik A L Biessen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Linsey J F Peters *Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).
Kiril Bidzhekov *Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).
Remco T A MegensInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).ORCID 0000-0001-9871-6696
Yvonne JansenInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).
Han JinCentral Laboratory, Tianjin Medical University General Hospital, China (H.J.).
Alexander JansDepartment of Medicine III (A.J., C.L., M.B.), University Hospital Aachen, Germany.
Cheng LinDepartment of Medicine III (A.J., C.L., M.B.), University Hospital Aachen, Germany.ORCID 0009-0007-2326-1536
Markus HaberboschInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).ORCID 0009-0004-7103-8345
Matthias BartneckDepartment of Medicine III (A.J., C.L., M.B.), University Hospital Aachen, Germany.ORCID 0000-0003-1516-9610
Erik A L BiessenDepartment of Pathology, CARIM, Maastricht UMC+, the Netherlands (H.J., E.A.L.B.).ORCID 0000-0002-6454-8548
Christian WeberInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).ORCID 0000-0003-4610-8714
Yvonne DöringInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).ORCID 0000-0001-9307-3396
Emiel P C van der VorstInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Germany (L.J.F.P., K.B., R.T.A.M., Y.J., M.H., C.W., Y.D., E.P.C.v.d.V.).ORCID 0000-0001-5771-6278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtherosclerosis is a leading cause of cardiovascular diseases, and microRNA-26b (miR-26b) has emerged as a significant regulator in its development. This study investigates the role of nonhematopoietic miR-26b in atherosclerosis.

methodsTo study the specific role of nonhematopoietic cell miR-26b in atherosclerosis development, we used a reverse bone marrow transplantation model combined with 12-week Western-type diet feeding.

resultsNonhematopoietic-specific miR-26b deficiency exacerbated atherosclerosis, characterized by larger plaques with increased collagen and necrotic core content. Enhanced VCAM-1 (vascular cell adhesion molecule 1) expression correlated with elevated leukocyte adhesion in ex vivo perfusion studies. Restoration of miR-26b levels in human coronary artery endothelial cells reduced inflammatory responses and leukocyte adhesion.

conclusionsOur findings highlight that nonhematopoietic miR-26b plays a protective role in atherosclerosis by modulating endothelial cell function, suggesting potential therapeutic applications for miR-26b mimics in cardiovascular disease management.

Indexed as

aorta, thoracicatherosclerosisbone marrow transplantationcardiovascular diseaseslipid nanoparticles

Identifiers

PMID41467351
PMCPMC12931848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.